AIS1
MCID: ATM052
MIFTS: 38

Autoimmune Disease 1 (AIS1)

Categories: Genetic diseases

Aliases & Classifications for Autoimmune Disease 1

MalaCards integrated aliases for Autoimmune Disease 1:

Name: Autoimmune Disease 1 57 74 29 6
Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 2 57 74
Autoimmune Disease, Susceptibility to, 1 57 13
Autoimmune Diseases 44 72
Vamas2 57 74
Ais1 57 74
Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 2; Vamas2 57
Autoimmune Disease Susceptibility Locus, Chromosome 1p-Related 57
Autoimmune Disease Susceptibility Locus Chromosome 1p-Related 74
Vitiligo-Associated Multiple Autoimmune Disease Type 2 74
Autoimmune Disease, Susceptibility to, Type 1 40
Autoimmune Disease Susceptibility 1 74

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
early age at onset (13 years)


HPO:

32
autoimmune disease 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 607836
MeSH 44 D001327
MedGen 42 C1842979
UMLS 72 C0004364

Summaries for Autoimmune Disease 1

UniProtKB/Swiss-Prot : 74 Autoimmune disease 1: An autoimmune disorder characterized by the association of vitiligo with autoimmune thyroiditis (Hashimoto thyroiditis).

MalaCards based summary : Autoimmune Disease 1, also known as vitiligo-associated multiple autoimmune disease susceptibility 2, is related to autoimmune disease 6 and autoimmune disease, multisystem, with facial dysmorphism. An important gene associated with Autoimmune Disease 1 is FOXD3 (Forkhead Box D3). The drugs Sofosbuvir and Ledipasvir have been mentioned in the context of this disorder. Affiliated tissues include thyroid, t cells and bone, and related phenotypes are hashimoto thyroiditis and vitiligo

More information from OMIM: 607836

Related Diseases for Autoimmune Disease 1

Diseases related to Autoimmune Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1301)
# Related Disease Score Top Affiliating Genes
1 autoimmune disease 6 12.5
2 autoimmune disease, multisystem, with facial dysmorphism 12.5
3 autoimmune disease, multisystem, infantile-onset, 1 12.5
4 autoimmune disease, multisystem, infantile-onset, 2 12.4
5 autoimmune disease 4 12.3
6 autoimmune disease of peripheral nervous system 12.3
7 systemic autoimmune disease 12.2
8 obsolete: vitiligo-associated autoimmune disease 12.2
9 autoimmune disease of central nervous system 12.1
10 autoimmune disease of endocrine system 12.1
11 autoimmune disease of eyes, ear, nose and throat 12.1
12 autoimmune disease of gastrointestinal tract 12.1
13 autoimmune disease of musculoskeletal system 12.1
14 autoimmune disease of skin and connective tissue 12.1
15 autoimmune disease of urogenital tract 12.1
16 autoimmune disease of blood 12.1
17 autoimmune disease of cardiovascular system 12.1
18 obsolete: other ganglionopathy related to autoimmune diseases 12.1
19 secondary neonatal autoimmune disease 12.1
20 autoimmune disease of exocrine system 12.1
21 sjogren's syndrome, juvenile, secondary to autoimmune disease 12.1
22 inflammatory and autoimmune disease with epilepsy 12.1
23 autoimmune disease with skin involvement 12.1
24 postinfectious autoimmune disease with chorea 12.1
25 vitiligo-associated multiple autoimmune disease susceptibility 1 11.7
26 itch e3 ubiquitin ligase deficiency 11.7
27 sjogren syndrome 11.6
28 graves' disease 11.5
29 celiac disease 6 11.5
30 celiac disease 1 11.5
31 scleroderma, familial progressive 11.5
32 pemphigus 11.5
33 rheumatoid arthritis 11.5
34 mixed connective tissue disease 11.5
35 myasthenia gravis 11.5
36 neuromyelitis optica 11.5
37 primary biliary cholangitis 11.4
38 stiff-person syndrome 11.4
39 goodpasture syndrome 11.4
40 multiple sclerosis 11.4
41 autoimmune hepatitis 11.4
42 igg4-related disease 11.4
43 interstitial lung disease 11.4
44 premature ovarian failure 1 11.4
45 microscopic polyangiitis 11.4
46 systemic scleroderma 11.4
47 undifferentiated connective tissue disease 11.4
48 lambert-eaton myasthenic syndrome 11.3
49 vogt-koyanagi-harada disease 11.3
50 cold agglutinin disease 11.3

Graphical network of the top 20 diseases related to Autoimmune Disease 1:



Diseases related to Autoimmune Disease 1

Symptoms & Phenotypes for Autoimmune Disease 1

Human phenotypes related to Autoimmune Disease 1:

32
# Description HPO Frequency HPO Source Accession
1 hashimoto thyroiditis 32 HP:0000872
2 vitiligo 32 HP:0001045

Symptoms via clinical synopsis from OMIM:

57
Skin Nails Hair Skin:
vitiligo, generalized
depigmentation, slowly progressive and diffuse

Endocrine Features:
hashimoto thyroiditis (some patients)

Clinical features from OMIM:

607836

Drugs & Therapeutics for Autoimmune Disease 1

Drugs for Autoimmune Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 531)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
2
Ledipasvir Approved Phase 4 1256388-51-8 67505836
3
Simvastatin Approved Phase 4 79902-63-9 54454
4
Azithromycin Approved Phase 4 83905-01-5 447043 55185
5
Azathioprine Approved Phase 4 446-86-6 2265
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
7
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
8
Insulin glargine Approved Phase 4 160337-95-1
9
Insulin Aspart Approved Phase 4 116094-23-6 16132418
10
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
11 Orange Approved Phase 4
12 Strawberry Approved Phase 4
13 Artichoke Approved Phase 4
14
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
15
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
16
leucovorin Approved Phase 4 58-05-9 143 6006
17
Etanercept Approved, Investigational Phase 4 185243-69-0
18
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
19
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
20
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
21
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
22
Artesunate Approved, Investigational Phase 4 88495-63-0 5464098 6917864
23
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
24
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
25
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 5271565 637568
26
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
27
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
28
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
29
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
30
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
31
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
32
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
33
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
35
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
36
Adefovir Investigational Phase 4 106941-25-7
37
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
38 Rosuvastatin Calcium Phase 4 147098-20-2
39 Lipid Regulating Agents Phase 4
40 Hypolipidemic Agents Phase 4
41 Anticholesteremic Agents Phase 4
42 Ledipasvir, sofosbuvir drug combination Phase 4
43 Omega 3 Fatty Acid Phase 4
44 Interferon alpha-2 Phase 4
45 Central Nervous System Depressants Phase 4
46 Estrogens Phase 4
47 Dihydroxycholecalciferols Phase 4
48 Insulin, Long-Acting Phase 4
49 Insulin degludec, insulin aspart drug combination Phase 4
50 Olive Phase 4

Interventional clinical trials:

(show top 50) (show all 800)
# Name Status NCT ID Phase Drugs
1 A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
2 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
3 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
4 A Phase IV, Single-site, Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum Unknown status NCT02199925 Phase 4 Gammaplex 5%
5 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
6 Open Label Study of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
7 Evaluation of Vaccination Against Influenza (Seasonal and H1N1) in Patients Presenting Systemic or Autoimmune Diseases Treated or Not With Steroids, and/or Immunosuppressant, and/or Biotherapy: an Open, Prospective Trial (MAIVAX) Completed NCT01065285 Phase 4
8 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
9 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
10 Influence of Plasma Exchange Therapy on the Pharmacokinetics of Rituximab in Patients Treated for Autoimmune Disorders. Completed NCT00820469 Phase 4 Rituximab 375;rituximab 1000
11 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
12 A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
13 Prospective, Randomized, Double Blind Placebo Controled Clinical Trial to Assess the Multi- Systemic Effect of Vitamin D Supplementation on Young Men With Vitamin D Deficiency Completed NCT01016184 Phase 4
14 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
15 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
16 The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia Completed NCT02192450 Phase 4 Insulin aspart/glargine;Insulin aspart/degludec
17 Effect of Ergocalciferol Repletion on Urine Calcium Among Stone Formers With Vitamin D Deficiency and Hypercalciuria Completed NCT01295879 Phase 4 Ergocalciferol
18 Pneumococcal Vaccination of Crohn Patients - A Randomized, Non-blinded Phase 4 Clinical Trial With the Purpose of Investigating the Immune Response Against Two Different Pneumococcal Vaccines in Patients With Crohn's Disease Completed NCT01947010 Phase 4
19 Comparison of Two Standard High-dose Treatment Regimens for Vitamin D Deficiency in Minority Adolescents: Associations of Vitamin D Repletion With Changes in Markers of Musculoskeletal, Cardiometabolic, and Immune Function Completed NCT01784029 Phase 4 Vitamin D3
20 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
21 EFFECTS OF A DIET RICH IN N-3 POLYUNSATURATED FATTY ACIDS ON SYSTEMIC INFLAMMATION IN RENAL TRANSPLANT RECIPIENTS Completed NCT01872455 Phase 4
22 SWITCH OR ADD PEGYLATED-INTERFERON IN CHRONIC HEPATITIS B PATIENTS ON LONG TERM NUCLEOS(T)IDE THERAPY (SWAP TRIAL) Completed NCT01928511 Phase 4 peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
23 Is Dietary Melatonin Supplementation a Viable Adjunctive Therapy for Chronic Periodontitis? A Preliminary Randomized Clinical Trial. Completed NCT03368430 Phase 4 Placebo
24 Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
25 Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential Recruiting NCT02419378 Phase 4 Alemtuzumab
26 Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects Recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
27 Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03540472 Phase 4 tacrolimus
28 Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03364764 Phase 4 Sirolimus
29 A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis: Pilot Study Recruiting NCT03214731 Phase 4 Artesunate
30 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Recruiting NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
31 Stopping Tumor Necrosis Factor-Alpha Inhibitors in Rheumatoid Arthritis (STARA) Clinical Trial Recruiting NCT01793519 Phase 4 Etanercept;Infliximab;Adalimumab;Placebo
32 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
33 A Multi-site, Open-Label, Pilot Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Active, not recruiting NCT03348618 Phase 4
34 Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients Active, not recruiting NCT03092544 Phase 4 dimethyl fumarate
35 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response. Active, not recruiting NCT03762824 Phase 4
36 Lactoferrin or Progesterone for Prevention of Preterm Delivery Active, not recruiting NCT02372942 Phase 4 Lattoferrin;Progesterone
37 Patient-Reported AutoImmunity Secondary to Cancer immunothErapy Not yet recruiting NCT03849131 Phase 4
38 Double-Blind, Randomized, Placebo-Controlled Trial of Naproxen Sodium for the Treatment of Obsessive Compulsive Symptoms in Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infections (PANDAS) Not yet recruiting NCT04015596 Phase 4 Naproxen Sodium
39 Silymarin® - Efficacy in Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) Controlled by Laboratory and and Elastographic Parameters Not yet recruiting NCT02973295 Phase 4 Silymarin
40 Efficacy of Fractional CO2 Laser Alone and as Transepidermal Drug Delivery for Different Modalities of Treatment in Alopecia Areata Not yet recruiting NCT04003376 Phase 4 Triamcinolone Acetonide 10mg/mL;vitamin D solution
41 A Phase 4 Multicenter, Randomized, Placebo Controlled Trial of 3 Doses of Intralesional Triamcinolone (KENALOG®) In the Treatment of Mild to Moderate Patch Type Alopecia Areata Terminated NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
42 Remission Keeping and Remission Inducing Effect by Vitamin-D in Crohns Disease, and in Vitro Vitamin-D Mediated T-Cell Immunomodulation Unknown status NCT00132184 Phase 2, Phase 3 Vitamin D
43 A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon Unknown status NCT00577304 Phase 3 Nitroglycerin;Topical AmphiMatrix
44 A Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20® (Mabion SA) Compared to MabThera® (Rituximab, Roche) in Patients With Rheumatoid Arthritis Unknown status NCT02468791 Phase 3 Rituximab
45 Prospective, Double-blind, Randomised, Placebo-controlled, Cross-over Study to Investigate the Effect of Intravenous Immunoglobulins on Complex Regional Pain Syndrome (CRPS, M. Sudeck) Unknown status NCT00949065 Phase 3
46 Prospective, Double-blind, Randomized, Controlled Clinical Trial of Low Dose Doxycycline in the Treatment of Corneal Burn Unknown status NCT01886560 Phase 2, Phase 3 Doxycycline;Placebo
47 T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis Unknown status NCT00228228 Phase 3
48 The Effect of Prednisone Versus Doxycycline in Active, Moderately Severe Graves' Orbitopathy: A Randomized, Multi-center, Double-blind, Parallel-controlled Trial Unknown status NCT01809444 Phase 2, Phase 3 Prednisone+placebo of Doxycycline;Doxycycline+placebo of Prednisone
49 Effects of Probiotics on Gastrointestinal Symptoms and on the Immune System in Patients With Systemic Sclerosis: a Randomized Double-blind Placebo-controlled Clinical Trial Unknown status NCT02302352 Phase 3
50 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3

Search NIH Clinical Center for Autoimmune Disease 1

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Methylprednisolone
methylprednisolone acetate
Methylprednisolone Sodium Succinate
Prednisone
PREDNISONE PWDR

Cochrane evidence based reviews: autoimmune diseases

Genetic Tests for Autoimmune Disease 1

Genetic tests related to Autoimmune Disease 1:

# Genetic test Affiliating Genes
1 Autoimmune Disease 1 29 FOXD3

Anatomical Context for Autoimmune Disease 1

MalaCards organs/tissues related to Autoimmune Disease 1:

41
Thyroid, T Cells, Bone, Bone Marrow, B Cells, Testes, Liver

Publications for Autoimmune Disease 1

Articles related to Autoimmune Disease 1:

(show all 24)
# Title Authors PMID Year
1
Candidate functional promoter variant in the FOXD3 melanoblast developmental regulator gene in autosomal dominant vitiligo. 8 71
16098053 2005
2
A genomewide screen for generalized vitiligo: confirmation of AIS1 on chromosome 1p31 and evidence for additional susceptibility loci. 38 8
12707860 2003
3
Mapping of an autoimmunity susceptibility locus (AIS1) to chromosome 1p31.3-p32.2. 38 8
11912181 2002
4
Mapping the major susceptibility loci for familial Graves' and Hashimoto's diseases: evidence for genetic heterogeneity and gene interactions. 8
10599734 1999
5
Characteristics of pedestrian head injuries observed from real world collision data. 38
31130209 2019
6
Genomics-Driven Immunoproteomics: An Integrative Platform to Uncover Important Biomarkers for Human Diseases. 38
31364060 2019
7
Immune mediated conditions in autism spectrum disorders. 38
25681541 2015
8
[INDICATIONS FOR ANTITHROMBOTIC MEDICATION DURING PREGNANCY--ANALYSIS OF CURRENT PRACTICES IN BULGARIA]. 38
26411189 2015
9
Airway management and endoscopic treatment of subglottic and tracheal stenosis: the laryngeal mask airway technique. 38
24671485 2014
10
Bicycle helmet wearing and the risk of head, face, and neck injury: a French case--control study based on a road trauma registry. 38
21606469 2012
11
[II. Autoimmune disease: 1. Systemic lupus erythematosus]. 38
21702138 2011
12
Unusual association between adrenal leiomyoma and autoimmune disease. 38
20174739 2010
13
Collagenous gastritis: histopathologic features and association with other gastrointestinal diseases. 38
19295410 2009
14
Biosynthesis of t-anethole in anise: characterization of t-anol/isoeugenol synthase and an O-methyltransferase specific for a C7-C8 propenyl side chain. 38
18987218 2009
15
Risk of permanent medical impairment (RPMI) in road traffic accidents. 38
19026226 2008
16
Minor crashes and 'whiplash' in the United States. 38
19026229 2008
17
Evidence for two susceptibility loci on chromosomes 22q12 and 6p21-p22 in Chinese generalized vitiligo families. 38
17568780 2007
18
Motor vehicle restraint system use and risk of spine injury. 38
16990240 2006
19
The first three years of the Swiss Neuropaediatric Stroke Registry (SNPSR): a population-based study of incidence, symptoms and risk factors. 38
15822021 2005
20
Influence of Airbags and Seatbelt Pretensioners on AIS1 Neck Injuries for Belted Occupants in Frontal Impacts. 38
17458722 2000
21
A Study of AIS1 Neck Injury Parameters in 168 Frontal Collisions Using a Restrained Hybrid III Dummy. 38
17458721 2000
22
Neck injuries in frontal impacts: influence of crash pulse characteristics on injury risk. 38
10688476 2000
23
CNS vasculitis in autoimmune disease: MR imaging findings and correlation with angiography. 38
9974060 1999
24
[Aortic valve replacement using aortic donor valves of human origin]. 38
8145864 1994

Variations for Autoimmune Disease 1

ClinVar genetic disease variations for Autoimmune Disease 1:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 FOXD3 FOXD3, -639G-T single nucleotide variant risk factor

Expression for Autoimmune Disease 1

Search GEO for disease gene expression data for Autoimmune Disease 1.

Pathways for Autoimmune Disease 1

GO Terms for Autoimmune Disease 1

Sources for Autoimmune Disease 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....